A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerElena Garralda, Gerald S. Falchook, Martin Wermke et al.|ESMO Open|2022Cited by 87
MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell TransplantationMartin Wermke, Uwe Platzbecker, Anne Schmidt et al.|Clinical Cancer Research|2012Cited by 72
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.Elena Garralda, Gerald S. Falchook, Ammar Sukari et al.|Journal of Clinical Oncology|2021Cited by 46
Abstract 1028: A tumor-agnostic YAP/TAZ score predicts TEAD inhibitor sensitivity independent of Hippo alterationsMichael Wegert-Verhoeven, Sebastian M. Dieter, Mathea Fransisca et al.|Cancer Research|2026Cited by 0